While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent ...

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

Rumors Linking Yung Miami to HIV Diagnosis Proven False A wave of concern and confusion hit social media this weekend. […] ...

A new report says the withdrawal of U.S. funding has caused a “systemic shock” to the global effort against AIDS and HIV.

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

Today, Pride is still an uprising. Keeping HIV awareness and prevention at the heart of Pride Month deepens its mission and ...

HIV/Aids breakthrough not a 'cure', popular social media posts misrepresent the factsIN SHORT: While promising, a recent breakthrough in HIV research is not a "cure" or a "vaccine", as several posts ...

The WHO issued a global recommendation for lenacapavir, a highly effective, twice-yearly injection to prevent HIV infection.

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

People living with HIV have a significantly increased risk of cardiovascular disease that requires a different level of preventive management than in the general population.

An inexpensive pill for treating HIV could become an alternative to injections for diabetic eye disease, a small study suggests.

Mike McCune said the Gates Foundation is “doubling down” on finding a cure for HIV during an ASGCT symposium.